Publications

Fond'action contre le cancer a financé les recherches ayant abouti aux publications scientifiques suivantes :

Laurent J., Speiser D.E., Appay V., Touvrey C., Vicari M., Papaioannou A., Canellini G., Rimoldi D., Rufer N., Romero P., Leyvraz S., Voelter V.
Impact of 3 Different Short-term Chemotherapy Regimens on Lymphocyte-depletion and Reconstitution in Melanoma Patients.
Journal of Immunotherapy, p. 1, 2010. [Texte] [Pubmed]


Voelter V., Rufer N., Reynard S., Greub G., Brookes R., Guillaume P., Grosjean F., Fagerberg T., Michielin O., Rowland-Jones S., Pinilla C., Leyvraz S., Romero P., Appay V.,
Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor.
International Immunology 20(8), pp. 1087-1096, 2008. [Texte] [Pubmed]


Michielin O., Rufer N., Romero P., Laurent J., Cerottini J.P., Gugisberg D., Leyvraz S., Speiser D.,
Nouveautés dans l'immunothérapie du cancer.
Revue Médicale Suisse, pp. 1248-1251, 21 mai 2008 [Texte]


Appay V., Bosio A., Lokan S., Wiencek Y., Biervert C., Küsters D., Devevre E., Speiser D., Romero P., Rufer N., Leyvraz S.,
Sensitive gene expression profiling of human T cell subsets reveals parallel post-thymic differentiation for CD4+ and CD8+ lineages.
Journal of Immunology 179(11), pp. 7406-7414, 2007. [Texte] [Pubmed]


Appay V., Voelter V., Rufer N., Reynard S., Jandus C., Gasparini D., Lienard D., Speiser D.E., Schneider P., Cerottini J.C., Romero P., Leyvraz S.,
Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.
Journal of Immunotherapy 30(2), pp. 240-250, 2007. [Texte] [Pubmed]


Appay V., Reynard S., Voelter V., Romero P., Speiser D.E., Leyvraz S.,
Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples.
Journal of immunological methods 309(1-2), pp. 192-9, 2006. [Texte] [Pubmed]


Appay V., Speiser D.E., Rufer N., Reynard S., Barbey C., Cerottini J.C., Leyvraz S., Pinilla C., Romero P.,
Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.
European journal of immunology 36(7), pp. 1805-14, 2006. [Pubmed]


 Appay V., Jandus C., Voelter V., Reynard V., Coupland S.E., Rimoldi D., Lienard D., Guillaume P., Krieg A.M., Cerottini J.C., Romero P., Leyvraz S., Rufer N., Speiser D.E.
New generation vaccine induces effective melanoma specific CD8+ T-cells in the circulation but not in the tumor site.
Journal of Immunology 177, pp. 1670-8, 2006. [Pubmed]


Montes M., Rufer N., Appay V., Reynard S., Pittet M.J., Speiser D.E., Guillaume P., Cerottini J.C., Romero P., Leyvraz S.
Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy.
Clinical & Experimental Immunology 142 : 292-302, 2005. [Pubmed]

Appay V.
T-cell based vaccines: where are we?
Expert Rev Anti Infect Ther. 2004 Aug.2 (4):463-5. Editorial.


Appay V.
The physiological role of cytotoxic CD4(+) T-cells: the holy grail?
Clinical & Experimental Immunology 2004 Oct; 138(1):10-3. Review.


Appay V.
Monitoring T cell directed vaccine trials in cancer patients: how to analyse cellular immune responses against tumour associated antigens.
Kluwer Academic Publishers. Book Chapter on Virus specific T-cell responses. In Press